Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06401824 | Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases | PHASE2 | RECRUITING | 25 | — | — | Apr 24, 2025 | Apr 1, 2027 | May 6, 2025 | 3 | Netherlands |
ORR is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) based on central and local investigator's assessment according to RANO-BM criteria on brain MRI
| Arm | Type | Description |
|---|---|---|
| sacituzumab govitecan (SG) plus bevacizumab | EXPERIMENTAL | SG 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression. |
| Name | Type | Description |
|---|---|---|
| Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab | DRUG | Sacituzumab govitecan 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression. |
Inclusion Criteria: * In order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. Signed informed consent must be obtained prior to participation in the study. 2. Participant is an adult ≥ 18 years of age at the time of informed consent. 3. ECO...